Trial Profile
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pelvic cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Triple negative breast cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms COSMIC-021
- Sponsors Exelixis
- 11 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Aug 2024.
- 11 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jul 2023.
- 18 Feb 2023 Results (n=32) of extended follow-up results of cohort 10 of the COSMIC-021 study, presented at the 2023 Genitourinary Cancers Symposium